



(51) International Patent Classification:

A61K 38/00 (2006.01) *A61K 38/17* (2006.01)*A61K 38/16* (2006.01)

(21) International Application Number:

PCT/US2018/062575

(22) International Filing Date:

27 November 2018 (27.11.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/590,911 27 November 2017 (27.11.2017) US

62/659,911 19 April 2018 (19.04.2018) US

(71) Applicant: CODA BIOTHERAPEUTICS, INC.

[US/US]; 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, California 94080 (US).

(72) Inventor; and

(71) Applicant: LAU, Anthony [US/US]; 280 Howland St., Apt. 102, Redwood City, California 94063 (US).

(72) Inventors: GREENBERG, Kenneth P.; 240 The Uplands, Berkeley, California 94705 (US). KEIFER, Orion, Jr.; 2080 Hanover Street, Palo Alto, California 94306 (US). MAKINSON, Stefanie; 2080 Hanover Street, Palo Alto, California 94306 (US).


(74) Agent: PHELAN, Jordan D. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES

Fig. 1



(57) Abstract: Compositions and methods are provided for modulating the activity of cells using engineered receptors, polynucleotide encoded engineered receptors, and gene therapy vectors comprising polynucleotides encoding engineered receptors. These compositions and methods find particular use in modulating the activity of neurons, for example in the treatment of disease or in the study of neuronal circuits.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))